KR100942863B1 - 인간 씨티엘에이-4 항체 및 그의 용도 - Google Patents
인간 씨티엘에이-4 항체 및 그의 용도 Download PDFInfo
- Publication number
- KR100942863B1 KR100942863B1 KR1020067017019A KR20067017019A KR100942863B1 KR 100942863 B1 KR100942863 B1 KR 100942863B1 KR 1020067017019 A KR1020067017019 A KR 1020067017019A KR 20067017019 A KR20067017019 A KR 20067017019A KR 100942863 B1 KR100942863 B1 KR 100942863B1
- Authority
- KR
- South Korea
- Prior art keywords
- human
- ctla
- antibody
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 370
- 101000633756 Echis pyramidum leakeyi Snaclec 4 Proteins 0.000 title 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract description 139
- 102000043321 human CTLA4 Human genes 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 117
- 210000004027 cell Anatomy 0.000 claims description 241
- 238000009739 binding Methods 0.000 claims description 179
- 230000027455 binding Effects 0.000 claims description 178
- 239000000427 antigen Substances 0.000 claims description 171
- 102000036639 antigens Human genes 0.000 claims description 167
- 108091007433 antigens Proteins 0.000 claims description 166
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 165
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 155
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 155
- 108090000623 proteins and genes Proteins 0.000 claims description 136
- 239000000203 mixture Substances 0.000 claims description 88
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 150000007523 nucleic acids Chemical class 0.000 claims description 72
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 230000028993 immune response Effects 0.000 claims description 45
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 108700019146 Transgenes Proteins 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 239000013612 plasmid Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 24
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 244000052769 pathogen Species 0.000 claims description 19
- 230000001717 pathogenic effect Effects 0.000 claims description 19
- 206010060862 Prostate cancer Diseases 0.000 claims description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000607720 Serratia Species 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 241000223935 Cryptosporidium Species 0.000 claims description 3
- 241001466953 Echovirus Species 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000224466 Giardia Species 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 241000222727 Leishmania donovani Species 0.000 claims description 3
- 206010024238 Leptospirosis Diseases 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 108010017842 Telomerase Proteins 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 208000006400 Arbovirus Encephalitis Diseases 0.000 claims description 2
- 241000193738 Bacillus anthracis Species 0.000 claims description 2
- 241000228405 Blastomyces dermatitidis Species 0.000 claims description 2
- 208000003508 Botulism Diseases 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 241000223205 Coccidioides immitis Species 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- 241000224432 Entamoeba histolytica Species 0.000 claims description 2
- 241000228404 Histoplasma capsulatum Species 0.000 claims description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 2
- 241000701460 JC polyomavirus Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241001245510 Lambia <signal fly> Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 241000235388 Mucorales Species 0.000 claims description 2
- 241000224438 Naegleria fowleri Species 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 102000013566 Plasminogen Human genes 0.000 claims description 2
- 108010051456 Plasminogen Proteins 0.000 claims description 2
- 241000223810 Plasmodium vivax Species 0.000 claims description 2
- 241000233872 Pneumocystis carinii Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000606651 Rickettsiales Species 0.000 claims description 2
- 241000710799 Rubella virus Species 0.000 claims description 2
- 241001149962 Sporothrix Species 0.000 claims description 2
- 241000295644 Staphylococcaceae Species 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 241000223105 Trypanosoma brucei Species 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 235000021168 barbecue Nutrition 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 229940096118 ella Drugs 0.000 claims description 2
- 229940007078 entamoeba histolytica Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 241000224422 Acanthamoeba Species 0.000 claims 1
- 241000223848 Babesia microti Species 0.000 claims 1
- 241000304886 Bacilli Species 0.000 claims 1
- 235000014653 Carica parviflora Nutrition 0.000 claims 1
- 241000243321 Cnidaria Species 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 241000194036 Lactococcus Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 241000282412 Homo Species 0.000 abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 37
- 201000010099 disease Diseases 0.000 abstract description 34
- 208000015181 infectious disease Diseases 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 95
- 239000012634 fragment Substances 0.000 description 94
- 241001465754 Metazoa Species 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 45
- 210000004602 germ cell Anatomy 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 44
- 108060003951 Immunoglobulin Proteins 0.000 description 43
- 102000018358 immunoglobulin Human genes 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 41
- 230000009261 transgenic effect Effects 0.000 description 41
- 229940027941 immunoglobulin g Drugs 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 210000004408 hybridoma Anatomy 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 238000011282 treatment Methods 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 31
- 210000003719 b-lymphocyte Anatomy 0.000 description 28
- 210000004698 lymphocyte Anatomy 0.000 description 28
- 230000001225 therapeutic effect Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 27
- 239000003814 drug Substances 0.000 description 26
- 238000011830 transgenic mouse model Methods 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 241000894007 species Species 0.000 description 24
- 238000002965 ELISA Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 241000699660 Mus musculus Species 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 20
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 20
- 230000004913 activation Effects 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 19
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 19
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 19
- 239000012636 effector Substances 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 19
- 108020001507 fusion proteins Proteins 0.000 description 19
- 102000037865 fusion proteins Human genes 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 18
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 18
- 239000013604 expression vector Substances 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 241001529936 Murinae Species 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- 230000006044 T cell activation Effects 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 13
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 13
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 13
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 13
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 206010069754 Acquired gene mutation Diseases 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 12
- 108010087819 Fc receptors Proteins 0.000 description 12
- 102000009109 Fc receptors Human genes 0.000 description 12
- 241000282553 Macaca Species 0.000 description 12
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000037439 somatic mutation Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 102000006354 HLA-DR Antigens Human genes 0.000 description 11
- 108010058597 HLA-DR Antigens Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229940072221 immunoglobulins Drugs 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000005215 recombination Methods 0.000 description 11
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 10
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 102100025304 Integrin beta-1 Human genes 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 210000002741 palatine tonsil Anatomy 0.000 description 9
- 230000008488 polyadenylation Effects 0.000 description 9
- 230000009257 reactivity Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108010047620 Phytohemagglutinins Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 230000005875 antibody response Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 230000001885 phytohemagglutinin Effects 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 6
- 102000005738 B7 Antigens Human genes 0.000 description 6
- 108010073807 IgG Receptors Proteins 0.000 description 6
- 102000009490 IgG Receptors Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 6
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000009830 antibody antigen interaction Effects 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 5
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 5
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 5
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 5
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 5
- 108010045634 B7 Antigens Proteins 0.000 description 5
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 5
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 5
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 5
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 5
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 5
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 5
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 5
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 5
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 5
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 5
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 5
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 5
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 5
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 5
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 5
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 5
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 5
- 101150117115 V gene Proteins 0.000 description 5
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 5
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 5
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 5
- 108010008355 arginyl-glutamine Proteins 0.000 description 5
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 5
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 5
- 108010089804 glycyl-threonine Proteins 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- -1 superoxide anions Chemical class 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- 108010044292 tryptophyltyrosine Proteins 0.000 description 5
- 229940030325 tumor cell vaccine Drugs 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 108010042653 IgA receptor Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 102000006240 membrane receptors Human genes 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 3
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 3
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 3
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 3
- 102000010910 CD28 Antigens Human genes 0.000 description 3
- 108010062433 CD28 Antigens Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101150097493 D gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 3
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 3
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 3
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 3
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 3
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- PRTZQMBYUZFSFA-XEGUGMAKSA-N Ile-Tyr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)O)N PRTZQMBYUZFSFA-XEGUGMAKSA-N 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 101150008942 J gene Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 3
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 3
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 3
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 3
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 3
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 3
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 3
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 3
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 3
- MYLNLEIZWHVENT-VKOGCVSHSA-N Val-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N MYLNLEIZWHVENT-VKOGCVSHSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 102000054751 human RUNX1T1 Human genes 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 108010051242 phenylalanylserine Proteins 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 2
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 2
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 2
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 2
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 2
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 2
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 2
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 2
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 2
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 2
- MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 2
- RVGMVLVBDRQVKB-UWVGGRQHSA-N Gly-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN RVGMVLVBDRQVKB-UWVGGRQHSA-N 0.000 description 2
- IXHQLZIWBCQBLQ-STQMWFEESA-N Gly-Pro-Phe Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IXHQLZIWBCQBLQ-STQMWFEESA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101100297421 Homarus americanus phc-2 gene Proteins 0.000 description 2
- 238000012450 HuMAb Mouse Methods 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 2
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 2
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- CWFGECHCRMGPPT-MXAVVETBSA-N Phe-Ile-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O CWFGECHCRMGPPT-MXAVVETBSA-N 0.000 description 2
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 2
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 2
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 2
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 2
- LHNNQVXITHUCAB-QTKMDUPCSA-N Thr-Met-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O LHNNQVXITHUCAB-QTKMDUPCSA-N 0.000 description 2
- HSQXHRIRJSFDOH-URLPEUOOSA-N Thr-Phe-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HSQXHRIRJSFDOH-URLPEUOOSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- YXSSXUIBUJGHJY-SFJXLCSZSA-N Trp-Thr-Phe Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)[C@H](O)C)C(O)=O)C1=CC=CC=C1 YXSSXUIBUJGHJY-SFJXLCSZSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 2
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 2
- 206010057362 Underdose Diseases 0.000 description 2
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 101710135378 pH 6 antigen Proteins 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000224424 Acanthamoeba sp. Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
- BFMIRJBURUXDRG-DLOVCJGASA-N Ala-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 BFMIRJBURUXDRG-DLOVCJGASA-N 0.000 description 1
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
- VQAVBBCZFQAAED-FXQIFTODSA-N Ala-Pro-Asn Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N VQAVBBCZFQAAED-FXQIFTODSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
- BEHQTVDBCLSCBY-CFMVVWHZSA-N Asn-Tyr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BEHQTVDBCLSCBY-CFMVVWHZSA-N 0.000 description 1
- GYNUXDMCDILYIQ-QRTARXTBSA-N Asp-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N GYNUXDMCDILYIQ-QRTARXTBSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000295636 Cryptosporidium sp. Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 241000527994 Cyclotella gamma Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- DLTCGJZBNFOWFL-LKTVYLICSA-N His-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N DLTCGJZBNFOWFL-LKTVYLICSA-N 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 101000629635 Homo sapiens Signal recognition particle receptor subunit alpha Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 1
- FPQMQEOVSKMVMA-ACRUOGEOSA-N Lys-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCCCN)N)O FPQMQEOVSKMVMA-ACRUOGEOSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100021974 Mus musculus Ltk gene Proteins 0.000 description 1
- 101000914483 Mus musculus T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 1
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BVLGVLWFIZFEAH-BPUTZDHNSA-N Ser-Pro-Trp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O BVLGVLWFIZFEAH-BPUTZDHNSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- 102100026900 Signal recognition particle receptor subunit alpha Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- YSXYEJWDHBCTDJ-DVJZZOLTSA-N Thr-Gly-Trp Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O YSXYEJWDHBCTDJ-DVJZZOLTSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 1
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 1
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000008841 allosteric interaction Effects 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000049849 human CD86 Human genes 0.000 description 1
- 102000056549 human Fv Human genes 0.000 description 1
- 108700005872 human Fv Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000727 immunotoxicological effect Effects 0.000 description 1
- 231100000619 immunotoxicology Toxicity 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003426 interchromosomal effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000012976 mRNA stabilization Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15045299P | 1999-08-24 | 1999-08-24 | |
| US60/150,452 | 1999-08-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027002451A Division KR20020047132A (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097003898A Division KR100996759B1 (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20060100950A KR20060100950A (ko) | 2006-09-21 |
| KR100942863B1 true KR100942863B1 (ko) | 2010-02-17 |
Family
ID=22534598
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067017019A Expired - Lifetime KR100942863B1 (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| KR1020097003898A Expired - Lifetime KR100996759B1 (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| KR1020027002451A Ceased KR20020047132A (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097003898A Expired - Lifetime KR100996759B1 (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| KR1020027002451A Ceased KR20020047132A (ko) | 1999-08-24 | 2000-08-24 | 인간 씨티엘에이-4 항체 및 그의 용도 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6984720B1 (enExample) |
| EP (4) | EP1212422B1 (enExample) |
| JP (4) | JP4093757B2 (enExample) |
| KR (3) | KR100942863B1 (enExample) |
| CN (2) | CN1371416B (enExample) |
| AT (1) | ATE354655T1 (enExample) |
| AU (3) | AU784012B2 (enExample) |
| BE (1) | BE2012C001I2 (enExample) |
| CA (2) | CA2589418A1 (enExample) |
| CY (2) | CY1107628T1 (enExample) |
| DE (2) | DE60033530T2 (enExample) |
| DK (1) | DK1212422T3 (enExample) |
| ES (1) | ES2282133T3 (enExample) |
| FR (1) | FR12C0004I2 (enExample) |
| IL (3) | IL148079A0 (enExample) |
| LU (1) | LU91928I2 (enExample) |
| MX (1) | MXPA02001911A (enExample) |
| NZ (1) | NZ517202A (enExample) |
| PT (1) | PT1212422E (enExample) |
| WO (1) | WO2001014424A2 (enExample) |
| ZA (1) | ZA200201190B (enExample) |
Families Citing this family (1064)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| AU774962B2 (en) * | 1998-12-03 | 2004-07-15 | Regents Of The University Of California, The | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| WO2000037504A2 (en) * | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) * | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| JP4986370B2 (ja) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Ｒｇｍおよびそのモジュレーターの用途 |
| EP1478751A4 (en) | 2001-03-30 | 2005-10-19 | Avigenics Inc | LYSOZYM PROMOTER IN BIRDS |
| US7541512B2 (en) | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| NZ536420A (en) * | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| CN1665533A (zh) * | 2002-05-02 | 2005-09-07 | 康涅狄格大学健康中心 | 热激蛋白用于增强抗体疗法功效的用途 |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| EP1542710B1 (en) | 2002-08-28 | 2012-09-26 | Dyax Corp. | Methods for preserving organs and tissues |
| JP2006513702A (ja) * | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| EP1549678A4 (en) * | 2002-09-30 | 2006-01-18 | Pfizer Prod Inc | HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE |
| WO2004035607A2 (en) * | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2373947T3 (es) * | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| JP4473257B2 (ja) | 2003-04-02 | 2010-06-02 | エフ．ホフマン−ラ ロシュ アーゲー | インスリン様成長因子ｉ受容体に対する抗体及びその使用 |
| EP1631312B1 (en) | 2003-04-23 | 2008-09-10 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
| US7465446B2 (en) * | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| KR20060034231A (ko) * | 2003-06-06 | 2006-04-21 | 메디뮨 인코포레이티드 | 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| EP1531162A1 (en) * | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
| US7642341B2 (en) | 2003-12-18 | 2010-01-05 | Merck Serono S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |
| EP1533617A1 (en) | 2003-11-19 | 2005-05-25 | RMF Dictagene S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer |
| ZA200604620B (en) | 2003-12-10 | 2007-10-31 | Medarex Inc | IP-10 antibodies and their uses |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| DK1766093T3 (da) | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf |
| BRPI0509274A (pt) * | 2004-03-26 | 2007-09-04 | Pfizer Prod Inc | usos de anticorpos anti-ctla-4 |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| US7378504B2 (en) | 2004-06-03 | 2008-05-27 | Medarex, Inc. | Human monoclonal antibodies to Fc gamma receptor I (CD64) |
| US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
| WO2006101503A2 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
| EP1781705B1 (en) | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| EP1827470A2 (en) * | 2004-12-09 | 2007-09-05 | Neuro Therapeutics AB | Materials and methods related to dickkopfs (dkk) and neurogenesis |
| CN101155832B (zh) | 2005-02-08 | 2013-02-06 | 一般财团法人化学及血清疗法研究所 | 抗体的改良方法 |
| AU2014240252B2 (en) * | 2005-03-08 | 2016-10-06 | Pfizer Products Inc | Anti-CTLA-4 Antibody Compositions |
| AU2012200203B2 (en) * | 2005-03-08 | 2014-07-03 | Pfizer Products Inc. | Anti-CTLA-4 Antibody Compositions |
| DK1865986T3 (en) * | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| US20080279865A1 (en) * | 2005-03-23 | 2008-11-13 | Pfizer, Inc., Pfizer Products, Inc. | Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| US20060240006A1 (en) * | 2005-04-20 | 2006-10-26 | Chishih Chu | Novel antibody structures derived from human germline sequences |
| DE102005019845A1 (de) * | 2005-04-28 | 2006-11-02 | Li-Te Chin | Neue aus humanen Keimbahnsequenzen gewonnene Antikörperstrukturen |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| CN101268101A (zh) * | 2005-07-07 | 2008-09-17 | 科利制药集团公司 | 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗 |
| CN100443503C (zh) * | 2005-07-18 | 2008-12-17 | 四川大学华西医院 | 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素 |
| CA2854576A1 (en) * | 2005-07-18 | 2007-01-25 | Haichun Huang | Human anti-b7rp1 neutralizing antibodies |
| NL1029605C2 (nl) * | 2005-07-25 | 2007-01-26 | Li-Te Chin | Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren. |
| EP2594591B1 (en) | 2005-08-11 | 2018-06-06 | Arpi Matossian-Rogers | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| EP1928905B1 (de) * | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| WO2007056540A2 (en) * | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| US8110194B2 (en) | 2005-12-07 | 2012-02-07 | Medarex, Inc. | CTLA-4 antibody dosage escalation regimens |
| WO2007067992A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| ES2396569T3 (es) | 2006-01-17 | 2013-02-22 | Medarex, Inc. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| EP2505058A1 (en) | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| EP2010226B1 (en) * | 2006-04-07 | 2014-01-15 | The Research Foundation of State University of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
| MX2008012754A (es) | 2006-04-07 | 2009-04-27 | Us Gov Health & Human Serv | Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica. |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| ES2396220T3 (es) | 2006-08-11 | 2013-02-20 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1) |
| WO2008030611A2 (en) | 2006-09-05 | 2008-03-13 | Medarex, Inc. | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| HRP20191115T1 (hr) | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| AU2007301599B2 (en) | 2006-09-28 | 2013-01-10 | Merck Serono S.A. | Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| PL2068922T3 (pl) | 2006-10-19 | 2012-11-30 | Csl Ltd | Przeciwciała anty-IL-13R alfa1 i ich zastosowania |
| US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
| CA2669921A1 (en) | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CN103172743B (zh) | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| US20100150950A1 (en) | 2006-12-14 | 2010-06-17 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| ES2537580T3 (es) | 2007-09-04 | 2015-06-09 | Compugen Ltd. | Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2560532T3 (es) | 2007-11-02 | 2016-02-19 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) |
| KR101615935B1 (ko) | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| EP2227296B1 (en) | 2008-01-08 | 2015-11-25 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| EP2240203B1 (en) | 2008-02-05 | 2014-04-09 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| CN102105787A (zh) * | 2008-05-29 | 2011-06-22 | 百时美施贵宝公司 | 用于预测患者对共刺激通道调节的应答的方法 |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
| CN102282265B (zh) * | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| WO2010067308A2 (en) | 2008-12-08 | 2010-06-17 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| PT2387627E (pt) | 2009-01-15 | 2016-06-03 | Adaptive Biotechnologies Corp | Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| BRPI1009232B1 (pt) | 2009-03-05 | 2022-05-03 | E.R. Squibb & Sons, Llc. | Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1 |
| EP3061463A1 (en) | 2009-04-08 | 2016-08-31 | LipUm AB | New methods for treatment of inflammatory diseases |
| US9062116B2 (en) | 2009-04-23 | 2015-06-23 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
| NO2424895T3 (enExample) | 2009-04-27 | 2018-02-03 | ||
| BRPI1016055A2 (pt) | 2009-04-27 | 2016-05-10 | Novartis Ag | composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12 |
| WO2010151632A1 (en) | 2009-06-25 | 2010-12-29 | Bristol-Myers Squibb Company | Protein purifacation by caprylic acid (octanoic acid ) precipitation |
| DK2769737T3 (en) | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
| WO2011037983A1 (en) | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Cation exchange chromatography |
| CA2775761C (en) * | 2009-09-30 | 2018-08-28 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CA2777226A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| HUE033758T2 (en) | 2009-10-26 | 2017-12-28 | Hoffmann La Roche | A method for producing glycosylated immunoglobulin |
| NO2501822T3 (enExample) | 2009-11-17 | 2018-01-13 | ||
| US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
| KR20120118002A (ko) | 2009-12-08 | 2012-10-25 | 애보트 게엠베하 운트 콤파니 카게 | 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체 |
| ES2905545T3 (es) * | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| JP2013527753A (ja) | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
| CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN105153307A (zh) | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| ES2659406T3 (es) | 2010-05-06 | 2018-03-15 | Novartis Ag | Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6) |
| US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
| WO2011146382A1 (en) | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| SMT201700547T1 (it) | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
| WO2012040617A2 (en) | 2010-09-23 | 2012-03-29 | Neogenix Oncology, Inc. | Colon and pancreas cancer peptidomimetics |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2013543384A (ja) | 2010-10-05 | 2013-12-05 | ノバルティス アーゲー | 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用 |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| SG191155A1 (en) | 2010-12-14 | 2013-07-31 | Univ Singapore | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US9409987B2 (en) | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| JP6177231B2 (ja) | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
| EP4520771A3 (en) | 2011-04-20 | 2025-07-16 | Genmab A/S | Bispecifc antibodies against her2 |
| JP2014514314A (ja) | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Ｈｅｒ２およびｃｄ３に対する二重特異性抗体 |
| JP6240063B2 (ja) | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート， インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US9067997B2 (en) | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
| EP2726503B1 (en) | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| MX340498B (es) | 2011-06-30 | 2016-07-11 | Chugai Pharmaceutical Co Ltd | Polipeptido heterodimerizado. |
| PL2726099T3 (pl) | 2011-07-01 | 2018-12-31 | Novartis Ag | Sposób leczenia zaburzeń metabolicznych |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
| BR112014004779B1 (pt) | 2011-08-30 | 2022-01-18 | Astex Pharmaceuticals, Inc | Formulações de derivados de decitabina, kit e processos relacionados |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| DK2579042T3 (da) | 2011-10-04 | 2014-07-21 | Affiris Ag | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
| JP2014530816A (ja) | 2011-10-14 | 2014-11-20 | ノバルティスアーゲー | Ｗｎｔ経路関連疾患のための抗体および方法 |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| EP2788382A2 (en) | 2011-12-05 | 2014-10-15 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| JP6336397B2 (ja) | 2011-12-14 | 2018-06-06 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 鉄関連障害を診断および治療するための組成物および方法 |
| WO2013090635A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
| KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| TW201336851A (zh) | 2012-02-13 | 2013-09-16 | 必治妥美雅史谷比公司 | 烯二炔化合物，其共軛物及彼等之用途與方法 |
| JP6302847B2 (ja) | 2012-03-05 | 2018-03-28 | アダプティヴ バイオテクノロジーズ コーポレーション | 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定 |
| US20150110779A1 (en) | 2012-03-15 | 2015-04-23 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
| US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| ES2711156T3 (es) | 2012-05-08 | 2019-04-30 | Adaptive Biotechnologies Corp | Método para medir y calibrar el sesgo de amplificación en reacciones de PCR multiplexadas |
| WO2013169971A1 (en) | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| TWI677507B (zh) | 2012-06-22 | 2019-11-21 | 達特茅斯學院基金會 | 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途 |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US9382329B2 (en) * | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| AU2013308595C1 (en) | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| EP2892558B1 (en) | 2012-09-07 | 2019-04-10 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| AU2013342163B2 (en) | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
| DK2925350T3 (da) | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| HRP20210517T1 (hr) | 2012-12-05 | 2021-05-14 | Novartis Ag | Pripravci i postupci za protutijela usmjerena na epo |
| KR20150095684A (ko) | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| WO2014106176A1 (en) | 2012-12-28 | 2014-07-03 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| AP2015008584A0 (en) | 2013-02-08 | 2015-07-31 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| SI2956173T1 (sl) | 2013-02-14 | 2017-06-30 | Bristol-Myers Squibb Company | Spojine tubulizina, postopki pridobivanja in uporaba |
| RU2019138702A (ru) | 2013-03-01 | 2020-01-27 | Астекс Фармасьютикалз, Инк. | Комбинации лекарственных средств |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| WO2014153150A1 (en) * | 2013-03-14 | 2014-09-25 | Lee Delphine J | Methods of predicting anti ctla-4 response and recurrence of cancer |
| WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
| JP6433085B2 (ja) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
| KR101472903B1 (ko) | 2013-05-16 | 2014-12-16 | (주)케어젠 | T 세포 활성 억제 펩타이드 및 이의 용도 |
| US20160115237A1 (en) | 2013-05-24 | 2016-04-28 | The University Of British Columbia | Cell senescence markers as diagnostic and therapeutic targets |
| WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
| AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| EP3030262B1 (en) | 2013-08-08 | 2019-10-09 | Cytune Pharma | Combined pharmaceutical composition |
| US11273204B2 (en) | 2013-08-08 | 2022-03-15 | Cytune Pharma | IL-15 and IL-15RAPLHA sushi domain based immunocytokines |
| TW201536318A (zh) | 2013-08-14 | 2015-10-01 | Novartis Ag | 治療偶發性包涵體肌炎之方法 |
| CN105899515B (zh) | 2013-08-14 | 2020-01-14 | 威廉马歇莱思大学 | uncialamycin的衍生物、合成方法及其作为抗肿瘤剂的用途 |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| JP6607850B2 (ja) | 2013-10-18 | 2019-11-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 |
| KR102196884B1 (ko) | 2013-11-01 | 2020-12-30 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| CN119775416A (zh) | 2013-12-24 | 2025-04-08 | 杨森制药公司 | 抗vista抗体及片段 |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3114144A1 (en) | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| ES2777529T3 (es) | 2014-04-17 | 2020-08-05 | Adaptive Biotechnologies Corp | Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| US20170158776A1 (en) | 2014-05-15 | 2017-06-08 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
| JP6997619B2 (ja) | 2014-06-11 | 2022-01-17 | キャシー・エイ・グリーン | 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用 |
| US20170290876A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Compositions and methods for long acting proteins |
| WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
| US20170291939A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
| US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| JP6843736B2 (ja) | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| EP3174902B1 (en) | 2014-08-01 | 2019-04-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An anti-cd45rc antibody for use as drug |
| WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
| SG10201805646WA (en) | 2014-08-07 | 2018-08-30 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
| CN106687124B (zh) | 2014-08-07 | 2022-03-15 | 冈村春树 | 并用il-18与分子靶向抗体的癌治疗药 |
| ES2743458T5 (es) * | 2014-08-08 | 2023-06-08 | Us Health | Eliminación fotocontrolada de dianas in vitro e in vivo |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| AU2015301753B2 (en) | 2014-08-12 | 2021-04-08 | Massachusetts Institute Of Technology | Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CA2944085C (en) | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
| MX391478B (es) | 2014-10-10 | 2025-03-21 | Idera Pharmaceuticals Inc | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer. |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| WO2016069886A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corporation | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| US10738078B2 (en) | 2014-11-03 | 2020-08-11 | Bristol-Myers Squibb Company | Use of caprylic acid precipitation for protein purification |
| DK4268843T3 (da) | 2014-11-07 | 2025-11-10 | F Hoffmann La Roche Ltd | Forbedrede IL-6-antistoffer |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| DK3221363T3 (da) | 2014-11-21 | 2020-08-10 | Bristol Myers Squibb Co | Antistoffer mod cd73 og anvendelser deraf |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| BR112017011538A2 (pt) | 2014-12-04 | 2018-03-13 | Bristol-Myers Squibb Company | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) |
| AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| MX2017008013A (es) | 2014-12-18 | 2018-03-06 | Amgen Inc | Formulacion congelada estable de virus de herpes simple. |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| CN104479019B (zh) * | 2014-12-26 | 2020-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗ctla-4人源抗体 |
| CA2972757A1 (en) | 2014-12-31 | 2016-07-07 | Arthur M. Krieg | Combination tumor immunotherapy |
| AU2016206808A1 (en) | 2015-01-14 | 2017-08-31 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3250588A1 (en) | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| WO2016138122A1 (en) | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
| KR102490956B1 (ko) | 2015-03-13 | 2023-01-19 | 브리스톨-마이어스 스큅 컴퍼니 | 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도 |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| US20180105554A1 (en) | 2015-03-20 | 2018-04-19 | Bristol-Myers Squibb Company | Use of dextran sulfate to enhance protein a affinity chromatography |
| US20180105555A1 (en) | 2015-03-20 | 2018-04-19 | Bristol-Myers Squibb Company | Use of dextran for protein purification |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| CA2981068C (en) | 2015-03-26 | 2021-12-14 | Women & Infants Hospital Of Rhode Island | Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors |
| WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| US10842848B2 (en) | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
| EP3281010B1 (en) | 2015-04-10 | 2020-12-30 | The Regents of The University of California | Methods of determining patient populations amenable to immunomodulatory treatment of cancer |
| NZ735820A (en) | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| US10211589B2 (en) | 2015-04-20 | 2019-02-19 | Mitsubishi Electric Corporation | Laser apparatus and extreme ultraviolet light generation apparatus |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| KR20170138555A (ko) | 2015-04-28 | 2017-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료 |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| EP3294334B1 (en) | 2015-05-11 | 2020-07-08 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| CA3025145A1 (en) | 2015-05-22 | 2016-12-01 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| WO2016191751A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| LT3303396T (lt) | 2015-05-29 | 2023-01-10 | Bristol-Myers Squibb Company | Antikūnai prieš ox40 ir jų panaudojimo būdai |
| US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| EA201792623A1 (ru) | 2015-06-03 | 2018-04-30 | Бостон Биомедикал, Инк. | Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака |
| CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| EP3722314A1 (en) | 2015-06-24 | 2020-10-14 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| ES2886657T3 (es) | 2015-06-29 | 2021-12-20 | Bristol Myers Squibb Co | Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer |
| BR112017028530A2 (pt) | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| MX2018000016A (es) | 2015-07-02 | 2019-01-31 | Otsuka Pharma Co Ltd | Composiciones farmaceuticas liofilizadas. |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| PL3322731T3 (pl) | 2015-07-14 | 2021-05-31 | Bristol-Myers Squibb Company | Sposób leczenia raka inhibitorem immunologicznych punktów kontrolnych; przeciwciałem, które wiąże się z receptorem programowanej śmierci-1 (pd-1) lub ligandem receptora programowanej śmierci 1 (pd-l1) |
| HK1248115A1 (zh) | 2015-07-16 | 2018-10-12 | Bioxcel Therapeutics, Inc. | 一种使用免疫调节治疗癌症的新颖方法 |
| CA2986705A1 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | A cxcr4 inhibitor and a pdi antagonist for use in treating cancer |
| US10660954B2 (en) | 2015-07-31 | 2020-05-26 | University Of Florida Research Foundation, Incorporated | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| KR102728071B1 (ko) | 2015-08-03 | 2024-11-11 | 노파르티스 아게 | Fgf21-연관 장애를 치료하는 방법 |
| US20180222990A1 (en) | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| SG10202111808WA (en) * | 2015-08-11 | 2021-11-29 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
| FI3334761T3 (fi) | 2015-08-13 | 2023-08-14 | Univ New York | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa |
| ES2955775T3 (es) | 2015-08-27 | 2023-12-07 | Inst Nat Sante Rech Med | Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| MX394957B (es) * | 2015-09-03 | 2025-03-24 | Ono Pharmaceutical Co | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". |
| MY186352A (en) | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| RS61763B1 (sr) | 2015-09-09 | 2021-05-31 | Novartis Ag | Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela |
| JP2018531625A (ja) | 2015-09-11 | 2018-11-01 | ナセント バイオテック インコーポレイテッド | 脳への向上した薬物送達の方法 |
| RU2638457C2 (ru) | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител |
| WO2017055326A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| WO2017055325A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of nk cells in a tissue sample |
| WO2017055324A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cells of monocytic origin in a tissue sample |
| WO2017055319A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of b cells in a tissue sample |
| WO2017055322A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of neutrophils in a tissue sample |
| WO2017055320A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample |
| WO2017055321A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of fibroblasts in a tissue sample |
| WO2017055327A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of endothelial cells in a tissue sample |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
| ES2994611T3 (en) | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| US10968277B2 (en) | 2015-10-22 | 2021-04-06 | Jounce Therapeutics, Inc. | Gene signatures for determining ICOS expression |
| WO2017079202A1 (en) | 2015-11-02 | 2017-05-11 | Board Of Regents, The University Of Texas System | Methods of cd40 activation and immune checkpoint blockade |
| JP2019503985A (ja) | 2015-11-03 | 2019-02-14 | グリコミメティクス， インコーポレイテッド | モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法 |
| CN108884159A (zh) | 2015-11-07 | 2018-11-23 | 茂体外尔公司 | 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物 |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| LT3377534T (lt) | 2015-11-18 | 2025-08-11 | Bristol-Myers Squibb Company | Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį |
| US11208483B2 (en) * | 2015-11-19 | 2021-12-28 | Shanghai Kanda Biotechnology Co, Ltd. | CTLA-4 antibodies and uses thereof |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| JP6849694B2 (ja) | 2015-11-30 | 2021-03-24 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗ヒトｉｐ−１０抗体およびそれらの使用 |
| CA3006759A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
| EP4015537A1 (en) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| CN116077648A (zh) | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| TW202208440A (zh) * | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| UY37030A (es) | 2015-12-18 | 2017-07-31 | Novartis Ag | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |
| WO2017112624A1 (en) | 2015-12-21 | 2017-06-29 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| EP4039699A1 (en) | 2015-12-23 | 2022-08-10 | ModernaTX, Inc. | Methods of using ox40 ligand encoding polynucleotides |
| AU2017206039B2 (en) | 2016-01-08 | 2021-03-25 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-N-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| CN113633634A (zh) | 2016-01-08 | 2021-11-12 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 |
| KR20180099712A (ko) | 2016-01-08 | 2018-09-05 | 셀진 코포레이션 | 항증식성 화합물, 및 이의 약제학적 조성물 및 용도 |
| US20190241658A1 (en) * | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| SG11201805621SA (en) | 2016-01-19 | 2018-08-30 | Pfizer | Cancer vaccines |
| WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| ES2924741T3 (es) | 2016-01-28 | 2022-10-10 | Inst Nat Sante Rech Med | Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario |
| ES2924775T3 (es) | 2016-01-28 | 2022-10-10 | Inst Nat Sante Rech Med | Métodos y composición farmacéutica para el tratamiento del cáncer |
| MX2018009800A (es) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos. |
| US20190046642A1 (en) | 2016-02-23 | 2019-02-14 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| WO2017144668A1 (en) | 2016-02-26 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for btla and uses thereof |
| KR20180118725A (ko) | 2016-03-04 | 2018-10-31 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| CA3016534A1 (en) | 2016-03-04 | 2017-09-08 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| RU2769314C1 (ru) | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| CN113549110B (zh) | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| JP7128399B2 (ja) | 2016-04-14 | 2022-08-31 | クリエイティブ マイクロテック インコーポレーテッド | 癌治療のための治療決定におけるｐｄ－ｌ１発現の使用方法 |
| EP3448412A4 (en) | 2016-04-15 | 2020-03-25 | Immunext Inc. | ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| CA3022377A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
| EA039084B1 (ru) | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Антитела к tl1a и их применения |
| WO2017196598A1 (en) | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| KR102469450B1 (ko) | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| DK3458474T3 (da) | 2016-05-18 | 2022-09-26 | Modernatx Inc | Kombinationer af mrna'er, der koder for immunmodulerende polypeptider og anvendelser deraf |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| CN109689694B (zh) | 2016-05-19 | 2022-11-22 | 通用医疗公司 | 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台 |
| HRP20240617T1 (hr) | 2016-05-20 | 2024-07-19 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN109689089A (zh) | 2016-05-25 | 2019-04-26 | 国家医疗保健研究所 | 治疗癌症的方法和组合物 |
| US11052148B2 (en) | 2016-05-30 | 2021-07-06 | Geo Vax, Inc. | Compositions and methods for generating an immune response to hepatitis B virus |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| FI3463457T3 (fi) | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa |
| JP2019517498A (ja) | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 |
| KR102702675B1 (ko) | 2016-06-03 | 2024-09-05 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| RU2018146946A (ru) | 2016-06-08 | 2020-07-10 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения |
| CN109563071B (zh) | 2016-06-08 | 2021-08-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4途径抑制剂的化学化合物 |
| CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| CN110381988A (zh) | 2016-06-15 | 2019-10-25 | 诺华股份有限公司 | 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| RU2760875C1 (ru) | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| WO2018011166A2 (en) | 2016-07-12 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| AU2017297603A1 (en) | 2016-07-14 | 2019-02-14 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤としてのイソキノリン誘導体 |
| EP3490561A4 (en) * | 2016-08-01 | 2020-04-08 | Ignyta, Inc. | COMBINATIONS FOR THE TREATMENT OF CANCER |
| NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
| JP2019528312A (ja) | 2016-08-07 | 2019-10-10 | ノバルティス アーゲー | ｍＲＮＡ媒介性の免疫化方法 |
| CN116640214A (zh) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | 分离抗体及其应用 |
| WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
| US10947268B2 (en) | 2016-08-12 | 2021-03-16 | Bristol-Myers Squibb Company | Methods of purifying proteins |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
| WO2018046736A1 (en) | 2016-09-12 | 2018-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from cancer |
| WO2018046738A1 (en) | 2016-09-12 | 2018-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from cancer |
| CA3036997A1 (en) | 2016-09-19 | 2018-03-22 | Oncoimmune, Inc. | Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| EP3515453A1 (en) | 2016-09-22 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
| CN117510643A (zh) | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| CN110383068A (zh) | 2016-10-03 | 2019-10-25 | 雅培实验室 | 评估患者样品中uch-l1状态的改进方法 |
| WO2018068182A1 (en) * | 2016-10-10 | 2018-04-19 | Crown Bioscience (Taicang) Inc. | Novel anti-ctla4 antibodies |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| JP7041136B2 (ja) | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔｕｓｃ２免疫療法のための方法および組成物 |
| WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
| EP4491237A3 (en) | 2016-10-28 | 2025-03-26 | Bristol-Myers Squibb Company | Methods of treating urothelial carcinoma using an anti-pd-1 antibody |
| KR102584340B1 (ko) | 2016-11-03 | 2023-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | 활성화가능한 항-ctla-4 항체 및 그의 용도 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP4545093A3 (en) | 2016-11-04 | 2025-08-20 | Aximmune, Inc. | Beta-alethine, immune modulatos, and uses thereof |
| AU2017356860A1 (en) * | 2016-11-08 | 2019-05-16 | Qilu Puget Sound Biotherapeutics Corporation | Anti-PD1 and anti-CTLA4 antibodies |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| EP3538112A4 (en) | 2016-11-09 | 2020-09-02 | Musc Foundation for Research Development | CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY |
| WO2018089829A1 (en) | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
| WO2018087391A1 (en) | 2016-11-14 | 2018-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation |
| US11339209B2 (en) | 2016-11-14 | 2022-05-24 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
| AU2017359944B2 (en) | 2016-11-15 | 2024-07-18 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| MA46852A (fr) | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| IL300095A (en) | 2016-11-23 | 2023-03-01 | Translational Drug Dev Llc | Benzamide and tumor necrosis factor receptor superfamily agonist compositions and uses thereof |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| CN106432499A (zh) * | 2016-11-24 | 2017-02-22 | 上海美迪西生物医药股份有限公司 | Ctla‑4抗体fab在昆虫表达系统中的制备方法 |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| BR112019011370A2 (pt) | 2016-12-01 | 2019-10-15 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
| EP3548068A1 (en) | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy |
| FI3551660T3 (fi) * | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN110168105B (zh) | 2016-12-09 | 2024-05-24 | 瑞泽恩制药公司 | 用于对t细胞受体进行测序的系统和方法及其用途 |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| WO2018112266A1 (en) | 2016-12-14 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| WO2018112360A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3558377A1 (en) | 2016-12-23 | 2019-10-30 | Virttu Biologics Limited | Treatment of cancer |
| EP3559029A2 (en) | 2016-12-23 | 2019-10-30 | Bristol-Myers Squibb Company | Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties |
| WO2018122249A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| WO2018122245A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting the survival time of patients suffering from cms3 colorectal cancer |
| EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
| TW201833140A (zh) | 2017-01-09 | 2018-09-16 | 美商莫瑞麥克製藥公司 | 抗fgfr抗體及使用方法 |
| JP2020505438A (ja) | 2017-01-10 | 2020-02-20 | ノダス・セラピューティクスＮｏｄｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ | インテグリン結合性ポリペプチド−Ｆｃ融合タンパク質および免疫調節物質を用いる併用がん治療法 |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| JP7062010B2 (ja) | 2017-01-27 | 2022-05-02 | セルジーン コーポレイション | ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ |
| EP3579885A4 (en) | 2017-02-07 | 2020-12-16 | Nantcell, Inc. | MAXIMIZING T CELL MEMORY, COMPOSITIONS AND RELATED METHODS |
| WO2018146148A1 (en) | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting the response to checkpoint blockade cancer immunotherapy |
| WO2018146128A1 (en) | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| JP6991246B2 (ja) | 2017-02-08 | 2022-02-03 | ノバルティス アーゲー | Ｆｇｆ２１模倣抗体及びその使用 |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| CA3054571A1 (en) | 2017-02-24 | 2018-08-30 | Board Of Regents,The University Of Texas System | Assay for detection of early stage pancreatic cancer |
| JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| US20180271996A1 (en) | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| BR112019017695A2 (pt) | 2017-02-28 | 2020-04-07 | Bristol-Myers Squibb Company | uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina |
| EP3366703B1 (en) | 2017-02-28 | 2019-04-03 | Ralf Kleef | Immune checkpoint therapy with hyperthermia |
| US20200150125A1 (en) | 2017-03-12 | 2020-05-14 | Yeda Research And Development Co., Ltd. | Methods of diagnosing and prognosing cancer |
| WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
| US20200009204A1 (en) | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| CN106916226B (zh) * | 2017-03-17 | 2020-01-14 | 信达生物制药(苏州)有限公司 | 以ctla-4为靶点的免疫调节药物治疗结核病的应用 |
| CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
| CA3054837A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Methods for preventing and treating heart disease |
| KR102660861B1 (ko) | 2017-03-30 | 2024-04-25 | 더 존스 홉킨스 유니버시티 | 생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템 |
| KR20250036268A (ko) | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2018187227A1 (en) | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| JP7344797B2 (ja) | 2017-04-15 | 2023-09-14 | アボット・ラボラトリーズ | 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法 |
| JP7718815B2 (ja) | 2017-04-21 | 2025-08-05 | シルラゼン， インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 |
| WO2018200430A1 (en) | 2017-04-26 | 2018-11-01 | Bristol-Myers Squibb Company | Methods of antibody production that minimize disulfide bond reduction |
| EP4063859A1 (en) | 2017-04-28 | 2022-09-28 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| WO2018200823A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
| US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| MX2019013648A (es) * | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| IL322309A (en) | 2017-05-24 | 2025-09-01 | Novartis Ag | IL2 antibody grafted proteins and methods of use in cancer treatment |
| IL270596B1 (en) | 2017-05-25 | 2025-09-01 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant region for use in treating cancer |
| AU2018272054B2 (en) | 2017-05-25 | 2024-10-31 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
| AU2018275236B2 (en) | 2017-05-30 | 2024-11-07 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I |
| BR112019018759A2 (pt) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| JP7657023B2 (ja) | 2017-06-09 | 2025-04-04 | プロビデンス ヘルス アンド サービシーズ－オレゴン | がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| JP2020524157A (ja) | 2017-06-20 | 2020-08-13 | アンスティテュート キュリー | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| EP3641812A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| JP2020525421A (ja) | 2017-06-28 | 2020-08-27 | ノバルティス アーゲー | 尿失禁を予防及び治療するための方法 |
| SMT202300068T1 (it) | 2017-06-30 | 2023-03-17 | Celgene Corp | Composizioni e metodi d'uso di 2-(4-clorofenil)-n-((2-(2,6-diossopiperidin-3-il)-1-ossoisoindolin-5-il)metil)-2,2-difluoroacetammide |
| US20200140383A1 (en) | 2017-07-03 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| US20210145771A1 (en) | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CA3068041C (en) | 2017-07-03 | 2024-06-25 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
| CN107325181A (zh) * | 2017-07-05 | 2017-11-07 | 无锡傲锐东源生物科技有限公司 | 抗ctla4蛋白单克隆抗体及其用途 |
| US10357489B2 (en) | 2017-07-10 | 2019-07-23 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| SG11202000197PA (en) | 2017-07-11 | 2020-02-27 | Pfizer | Immunogenic compositions comprising cea muc1 and tert |
| SG11202000248UA (en) | 2017-07-14 | 2020-02-27 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| EP3658173A1 (en) | 2017-07-25 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| MX2020001233A (es) | 2017-08-03 | 2020-07-20 | Otsuka Pharma Co Ltd | Compuesto farmaceutico y metodos de purificacion del mismo. |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| KR102758037B1 (ko) | 2017-08-18 | 2025-01-22 | 코테라 바이오사이언스 인코포레이티드 | Tg02의 다형성 형태 |
| US11745165B2 (en) | 2017-08-18 | 2023-09-05 | The Johns Hopkins University | Supramolecular filamentous assemblies for protein purification |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| US20210060158A1 (en) | 2017-09-19 | 2021-03-04 | Institut Curie | Agonist of aryl hydrocarbon receptor for use in cancer combination therapy |
| RU2020113600A (ru) | 2017-09-20 | 2021-10-20 | Ридженерон Фармасьютикалз, Инк. | Способы иммунотерапии пациентов, опухоли которых характеризуются высокой нагрузкой пассажирскими генными мутациями |
| EP3691643A4 (en) | 2017-09-29 | 2021-06-16 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER |
| JP2020536106A (ja) | 2017-10-05 | 2020-12-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| BR112020006780A2 (pt) | 2017-10-05 | 2020-10-06 | Glaxosmithkline Intellectual Property Development Limited | moduladores do estimulador de genes do interferon (sting) |
| US12178787B2 (en) | 2017-10-12 | 2024-12-31 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| JP2021501801A (ja) | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| EP3707165A4 (en) | 2017-11-07 | 2021-09-08 | The Board of Regents of The University of Texas System | TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN CANCER TREATMENT |
| ES2939112T3 (es) | 2017-11-10 | 2023-04-19 | Armo Biosciences Inc | Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario |
| CA3082287C (en) | 2017-11-14 | 2023-02-28 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| US11679148B2 (en) | 2017-11-24 | 2023-06-20 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for treating cancers |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| JP7344801B2 (ja) | 2017-12-09 | 2023-09-14 | アボット・ラボラトリーズ | グリア原線維性酸性タンパク質（ｇｆａｐ）及び／又はユビキチンカルボキシ末端ヒドロラーゼｌ１（ｕｃｈ－ｌ１）を使用する、整形外科損傷を負っており、軽度外傷性脳損傷（ｔｂｉ）などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法 |
| US11016105B2 (en) | 2017-12-09 | 2021-05-25 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| RU2756100C1 (ru) | 2017-12-20 | 2021-09-28 | Харбор Байомед (Шанхай) Ко., Лтд | Антитела, связывающие ctla-4, и их применение |
| EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| CN117050184A (zh) | 2017-12-28 | 2023-11-14 | 南京传奇生物科技有限公司 | 针对tigit的单域抗体和其变体 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
| EP3737362B1 (en) | 2018-01-12 | 2025-10-15 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| KR102813913B1 (ko) | 2018-01-12 | 2025-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| JP7366908B2 (ja) | 2018-01-15 | 2023-10-23 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｐｄ－１に対する単一ドメイン抗体及びその変異体 |
| WO2019143607A1 (en) | 2018-01-16 | 2019-07-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| MX2020007526A (es) | 2018-01-22 | 2020-09-09 | Bristol Myers Squibb Co | Composiciones y metodos para tratar el cancer. |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| EP3752194A4 (en) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| US20210032334A1 (en) | 2018-02-28 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| CN111867679A (zh) | 2018-03-06 | 2020-10-30 | 居里研究所 | 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂 |
| SG11202008696RA (en) | 2018-03-12 | 2020-10-29 | Inst Nat Sante Rech Med | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers |
| CN110272490B (zh) * | 2018-03-14 | 2021-05-14 | 上海开拓者生物医药有限公司 | 靶向ctla-4抗体、其制备方法和用途 |
| MX394121B (es) | 2018-03-14 | 2025-03-24 | Surface Oncology Inc | Anticuerpos que se unen a cd39 y sus usos |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| EP4066851A1 (en) | 2018-03-25 | 2022-10-05 | SNIPR Biome ApS. | Treating & preventing microbial infections |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| BR112020019251A2 (pt) | 2018-03-27 | 2021-01-12 | Board Of Regents, The University Of Texas System | Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19 |
| KR20200136464A (ko) | 2018-03-29 | 2020-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단량체성 모노클로날 항체를 정제하는 방법 |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| EP3775218A1 (en) | 2018-04-09 | 2021-02-17 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| JOP20200243A1 (ar) | 2018-04-09 | 2020-09-29 | Eisai R&D Man Co Ltd | مركبات البلاديينوليد واستخداماتها |
| CN117285502A (zh) | 2018-04-12 | 2023-12-26 | 卫材R&D管理有限公司 | 作为用于治疗癌症的剪接体靶向剂的普拉二烯内酯衍生物 |
| US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
| WO2019209896A1 (en) | 2018-04-25 | 2019-10-31 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| SG11202009986QA (en) | 2018-05-07 | 2020-11-27 | Genmab As | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN113713095B (zh) | 2018-05-23 | 2025-07-15 | 细胞基因公司 | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 |
| US10969381B2 (en) | 2018-05-23 | 2021-04-06 | Celgene Corporation | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile |
| EP3801629A1 (en) | 2018-05-29 | 2021-04-14 | Bristol-Myers Squibb Company | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| CN112203688A (zh) | 2018-05-31 | 2021-01-08 | 小野药品工业株式会社 | 用于确定免疫检查点抑制剂的有效性的生物标志物 |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| IL278740B2 (en) | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| IL305431B2 (en) | 2018-06-01 | 2025-03-01 | Eisai R&D Man Co Ltd | Antibody-drug conjugates of splicing modulators and methods of use |
| WO2019232523A1 (en) | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
| CN112566643A (zh) | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| CA3102334A1 (en) | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
| JP2021529814A (ja) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| AU2019302454A1 (en) | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| CN118147029A (zh) | 2018-07-11 | 2024-06-07 | 阿克蒂姆治疗有限公司 | 工程化的免疫刺激性细菌菌株及其用途 |
| US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| EP3833383A1 (en) | 2018-08-06 | 2021-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| JP7433291B2 (ja) | 2018-08-16 | 2024-02-19 | イネイト・テューマー・イミュニティ・インコーポレイテッド | イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター |
| EP3837014B1 (en) | 2018-08-16 | 2022-10-19 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| WO2020048942A1 (en) | 2018-09-04 | 2020-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses |
| WO2020049534A1 (en) | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
| CN113056487A (zh) | 2018-09-18 | 2021-06-29 | 梅里麦克制药股份有限公司 | 抗tnfr2抗体及其用途 |
| JP7618950B2 (ja) | 2018-09-19 | 2025-01-22 | インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
| CN113544144A (zh) | 2018-09-19 | 2021-10-22 | 高山免疫科学股份有限公司 | 变体cd80融合蛋白和相关构建体的方法和用途 |
| US20230132385A9 (en) * | 2018-09-20 | 2023-04-27 | Tikcro Technologies Ltd. | Antibodies specific to ctla-4 and uses thereof |
| JP7512210B2 (ja) | 2018-09-21 | 2024-07-08 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 新規インターロイキン２およびその使用 |
| US20210213102A1 (en) | 2018-09-21 | 2021-07-15 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| EP3860578A1 (en) | 2018-10-01 | 2021-08-11 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| EP3867269A1 (en) | 2018-10-18 | 2021-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor |
| KR20210081384A (ko) | 2018-10-23 | 2021-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| AU2019369340A1 (en) | 2018-10-29 | 2021-05-20 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| AU2019371223B2 (en) * | 2018-10-31 | 2022-03-17 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20220001026A1 (en) | 2018-11-08 | 2022-01-06 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| CN113330310A (zh) | 2018-11-09 | 2021-08-31 | 皮埃里亚生物科学有限责任公司 | 用于测定肿瘤微环境组成的方法和组合物 |
| WO2020102728A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| JP2022507495A (ja) | 2018-11-16 | 2022-01-18 | アーキュール・インコーポレイテッド | 癌治療のための医薬の組合せ |
| WO2020106621A1 (en) | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US20220016277A1 (en) | 2018-11-20 | 2022-01-20 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
| WO2020109328A1 (en) | 2018-11-26 | 2020-06-04 | Debiopharm International S.A. | Combination treatment of hiv infections |
| EP3888648A4 (en) | 2018-11-27 | 2022-08-10 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND FOLFIRINOX THERAPY |
| AU2019386140A1 (en) | 2018-11-28 | 2021-06-24 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| KR20210096167A (ko) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| US20220018828A1 (en) | 2018-11-28 | 2022-01-20 | Inserm (Institut National De La Santé Et La Recherche Médicale | Methods and kit for assaying lytic potential of immune effector cells |
| CN113316455A (zh) | 2018-11-29 | 2021-08-27 | 得克萨斯大学体系董事会 | 用于离体扩增自然杀伤细胞的方法及其用途 |
| HUE062089T2 (hu) | 2018-11-30 | 2023-09-28 | Rao Naik Chetana | Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások |
| WO2020110056A1 (en) | 2018-11-30 | 2020-06-04 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in hiv therapy |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| EP3891270A1 (en) | 2018-12-07 | 2021-10-13 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
| CN113195467A (zh) | 2018-12-11 | 2021-07-30 | 施万生物制药研发Ip有限责任公司 | 适用作alk5抑制剂的萘啶和喹啉衍生物 |
| US12478686B2 (en) | 2018-12-12 | 2025-11-25 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
| KR20210102274A (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 |
| US20220047556A1 (en) | 2018-12-17 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sulconazole as a furin inhibitor |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
| CN119930820A (zh) * | 2018-12-27 | 2025-05-06 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| IL284421B2 (en) | 2018-12-28 | 2025-05-01 | Transgene | M2-defective poxvirus |
| KR20220008253A (ko) | 2019-01-03 | 2022-01-20 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물 |
| US11779580B2 (en) | 2019-01-09 | 2023-10-10 | Celgene Corporation | Pharmaceutical compositions comprising (s)-4-(4-(4- (((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrtle and methods of using the |
| FI3908281T3 (fi) | 2019-01-09 | 2024-10-01 | Celgene Corp | Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa |
| CN118324742A (zh) | 2019-01-09 | 2024-07-12 | 细胞基因公司 | 包含氧代异吲哚化合物及其盐的固体形式,以及包含它们的组合物和它们的使用方法 |
| EP3911641A1 (en) | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2020150114A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
| WO2020150116A1 (en) | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| EP3911416B1 (en) | 2019-01-14 | 2024-06-12 | Innate Tumor Immunity, Inc. | Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer |
| JP7645185B2 (ja) | 2019-01-15 | 2025-03-13 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | 変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用 |
| US11008395B2 (en) | 2019-01-22 | 2021-05-18 | Bristol Myers-Squibb Company | Antibodies against IL-7R alpha subunit and uses thereof |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| CA3128064A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| WO2020169472A2 (en) | 2019-02-18 | 2020-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing phenotypic changes in macrophages |
| CA3131953A1 (en) | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| KR20210135532A (ko) | 2019-03-05 | 2021-11-15 | 암젠 인크 | 암 치료를 위한 종양 용해 바이러스의 용도 |
| AU2020234785A1 (en) | 2019-03-13 | 2021-08-19 | Merck Sharp & Dohme Llc | Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| US20220184121A1 (en) | 2019-03-18 | 2022-06-16 | The Regents Of The University Of California | Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells |
| MX2021011753A (es) | 2019-03-26 | 2022-01-31 | Univ Michigan Regents | Degradadores de moleculas peque?as de stat3. |
| US20220195046A1 (en) | 2019-03-28 | 2022-06-23 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20220041733A1 (en) | 2019-03-28 | 2022-02-10 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| US20220193198A1 (en) | 2019-03-29 | 2022-06-23 | Institut Curie | Interleukin-2 Variants with Modified Biological Activity |
| JP7570344B2 (ja) | 2019-03-29 | 2024-10-21 | ブリストル－マイヤーズ スクイブ カンパニー | クロマトグラフィー樹脂の疎水性を測定する方法 |
| EP3947403A1 (en) | 2019-03-29 | 2022-02-09 | The Regents Of The University Of Michigan | Stat3 protein degraders |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3947640A4 (en) | 2019-04-02 | 2022-12-14 | The Brigham & Women's Hospital, Inc. | PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA |
| WO2020208060A1 (en) | 2019-04-09 | 2020-10-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer |
| US20220220480A1 (en) | 2019-04-17 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| EP3955960B1 (en) | 2019-04-18 | 2025-01-15 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| AU2020268199B2 (en) | 2019-05-09 | 2025-08-21 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
| JP2022533390A (ja) | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| CN114096240A (zh) | 2019-05-17 | 2022-02-25 | 癌症预防制药股份有限公司 | 用于治疗家族性腺瘤性息肉病的方法 |
| JP2022533791A (ja) | 2019-05-20 | 2022-07-25 | マサチューセッツ インスティテュート オブ テクノロジー | ボロン酸エステルプロドラッグおよびそれらの使用 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2020247973A1 (en) | 2019-06-03 | 2020-12-10 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
| US20220298225A1 (en) | 2019-06-03 | 2022-09-22 | The University Of Chicago | Methods and compositions for treating cancer with collagen binding drug carriers |
| US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| WO2020252336A1 (en) | 2019-06-12 | 2020-12-17 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| CN114222729A (zh) | 2019-06-12 | 2022-03-22 | 范德比尔特大学 | 氨基酸转运抑制剂及其用途 |
| BR112021025476A2 (pt) | 2019-06-26 | 2022-10-11 | Glaxosmithkline Ip Dev Ltd | Proteínas de ligação à il1rap |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| US12485174B2 (en) | 2019-06-27 | 2025-12-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | HDAC6-activated macrophages, compositions, and uses thereof |
| US20220257796A1 (en) | 2019-07-02 | 2022-08-18 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| WO2021011713A1 (en) | 2019-07-16 | 2021-01-21 | The Regents Of The University Of Michigan | Imidazopyrimidines as eed inhibitors and the use thereof |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| BR112021005478A2 (pt) | 2019-07-24 | 2021-06-15 | H. Lundbeck A/S | anticorpos anti-mglur5 e uso dos mesmos |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP3778875A1 (en) | 2019-08-14 | 2021-02-17 | MaxiVax SA | Immortalized myoblast cell lines and uses thereof |
| US11851490B2 (en) | 2019-08-15 | 2023-12-26 | Northwestern University | Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification |
| GB201912107D0 (en) | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| WO2021041664A1 (en) | 2019-08-27 | 2021-03-04 | The Regents Of The University Of Michigan | Cereblon e3 ligase inhibitors |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| JP2022548484A (ja) | 2019-09-16 | 2022-11-21 | サーフィス オンコロジー インコーポレイテッド | 抗ｃｄ３９抗体の組成物及び方法 |
| US20240377413A1 (en) | 2019-09-16 | 2024-11-14 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| WO2021055627A1 (en) | 2019-09-17 | 2021-03-25 | Bial- Biotech Investments, Inc. | Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments |
| WO2021055612A1 (en) | 2019-09-17 | 2021-03-25 | BIAL-BioTech Investments, Inc. | Substituted imidazole carboxamides and their use in the treatment of medical disorders |
| CN114901652A (zh) | 2019-09-17 | 2022-08-12 | 比亚尔R&D投资股份公司 | 用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| CN115023267A (zh) | 2019-09-19 | 2022-09-06 | 密歇根大学董事会 | 螺环雄激素受体蛋白质降解剂 |
| CN114729043A (zh) | 2019-09-19 | 2022-07-08 | 百时美施贵宝公司 | 在酸性pH下结合至VISTA的抗体 |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| CA3151747A1 (en) | 2019-09-23 | 2021-04-01 | James J. MOON | Compositions and methods for increasing the efficacy of immunotherapies and vaccines |
| JP7122354B2 (ja) | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗ｔｉｇｉｔ抗体および使用方法 |
| TW202521984A (zh) | 2019-09-25 | 2025-06-01 | 美商表面腫瘤學有限責任公司 | 抗ｉｌ－２７抗體及其用途 |
| EP3800201A1 (en) | 2019-10-01 | 2021-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd28h stimulation enhances nk cell killing activities |
| US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| EP4048304A1 (en) | 2019-10-22 | 2022-08-31 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| US11459389B2 (en) | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
| WO2021079958A1 (ja) | 2019-10-25 | 2021-04-29 | 第一三共株式会社 | 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ |
| NL2024107B1 (en) | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| NL2024108B1 (en) | 2019-10-26 | 2021-07-19 | Vitroscan B V | Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses |
| US20220380765A1 (en) | 2019-11-02 | 2022-12-01 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
| CN115397472A (zh) | 2019-11-04 | 2022-11-25 | 思进股份有限公司 | 抗cd30抗体-药物缀合物及其用于治疗hiv感染的用途 |
| BR112022008677A2 (pt) | 2019-11-05 | 2022-07-19 | Celgene Corp | Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| AU2020380732A1 (en) | 2019-11-07 | 2022-06-02 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| TWI895295B (zh) | 2019-11-12 | 2025-09-01 | 美商方得生醫療公司 | 偵測編碼新生抗原之融合基因之方法 |
| PH12022551150A1 (en) * | 2019-11-15 | 2023-10-09 | Genzyme Corp | Biparatopic cd73 antibodies |
| EP3824954A1 (en) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Device, apparatus and method for minibeam radiation therapy |
| JP2023502662A (ja) | 2019-11-22 | 2023-01-25 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン |
| JPWO2021106978A1 (enExample) | 2019-11-27 | 2021-06-03 | ||
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| BR112022009631A2 (pt) | 2019-12-19 | 2022-08-09 | Bristol Myers Squibb Co | Combinações de inibidores de dgk e antagonistas do ponto de checagem |
| EP4082570A4 (en) | 2019-12-27 | 2023-09-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CTLA-4 ANTIBODIES AND USE THEREOF |
| JP2023509516A (ja) | 2020-01-07 | 2023-03-08 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種 |
| KR20220127848A (ko) | 2020-01-10 | 2022-09-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| EP4096718A1 (en) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| US20230087600A1 (en) | 2020-02-06 | 2023-03-23 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
| EP4107173A1 (en) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| WO2021183318A2 (en) | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| EP3878446A1 (en) | 2020-03-09 | 2021-09-15 | Universite De Geneve | Hsd11b1 inhibitors for use in immunotherapy and uses thereof |
| US20230159573A1 (en) | 2020-03-26 | 2023-05-25 | The Regents Of The University Of Michigan | Small molecule stat protein degraders |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| JP2023519673A (ja) | 2020-03-31 | 2023-05-12 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 置換ピリミジンおよび使用方法 |
| JPWO2021205631A1 (enExample) | 2020-04-10 | 2021-10-14 | ||
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2021211331A1 (en) | 2020-04-13 | 2021-10-21 | Abbott Point Of Care Inc. | METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE |
| US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
| CA3175499A1 (en) | 2020-04-21 | 2021-10-28 | University Of Rochester | Inhibitors of human epididymus protein 4 |
| IL297442A (en) | 2020-04-22 | 2022-12-01 | Iovance Biotherapeutics Inc | Systems and methods for coordinating production of cells for patient-specific immunotherapy |
| JP2023523794A (ja) | 2020-05-01 | 2023-06-07 | ノバルティス アーゲー | 人工操作免疫グロブリン |
| CN115461363A (zh) | 2020-05-01 | 2022-12-09 | 诺华股份有限公司 | 免疫球蛋白变体 |
| WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021228178A1 (en) | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| CA3182333A1 (en) | 2020-05-20 | 2021-11-25 | Institut Curie | Single domain antibodies and their use in cancer therapies |
| CN115803084A (zh) | 2020-05-21 | 2023-03-14 | 得克萨斯大学体系董事会 | 具有vgll1特异性的t细胞受体和其用途 |
| CN115803343A (zh) * | 2020-05-26 | 2023-03-14 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| EP4157319A1 (en) | 2020-05-28 | 2023-04-05 | Modernatx, Inc. | Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer |
| CA3180060A1 (en) | 2020-05-29 | 2021-12-02 | Zongmin ZHAO | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes |
| AU2021285044A1 (en) | 2020-06-03 | 2022-12-08 | Institute For Research In Biomedicine | Combination of an ATP-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
| WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
| EP4165041A1 (en) | 2020-06-10 | 2023-04-19 | Theravance Biopharma R&D IP, LLC | Naphthyridine derivatives useful as alk5 inhibitors |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| JP2023531512A (ja) | 2020-06-25 | 2023-07-24 | セルジーン コーポレーション | 併用療法を用いて癌を治療するための方法 |
| BR112022025105A2 (pt) | 2020-06-29 | 2023-01-17 | Genmab As | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco |
| EP4172628A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| WO2022002873A1 (en) | 2020-06-30 | 2022-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
| DK4178548T3 (da) | 2020-07-07 | 2024-08-19 | Celgene Corp | Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| US20230257365A1 (en) | 2020-07-10 | 2023-08-17 | The Regents Of The University Of Michigan | Small molecule androgen receptor protein degraders |
| WO2022011205A1 (en) | 2020-07-10 | 2022-01-13 | The Regents Of The University Of Michigan | Androgen receptor protein degraders |
| CN115812081A (zh) | 2020-07-21 | 2023-03-17 | 上海君实生物医药科技股份有限公司 | 抗ctla-4抗体及其用途 |
| US20230295146A1 (en) | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| KR20230042301A (ko) | 2020-08-04 | 2023-03-28 | 애벗트 라보라토리이즈 | 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트 |
| US11988671B2 (en) | 2020-08-04 | 2024-05-21 | Abbott Rapid Diagnostics International Unlimited Company | Assays for detecting SARS-CoV-2 |
| KR20230066149A (ko) | 2020-08-07 | 2023-05-12 | 포티스 테라퓨틱스, 인크. | Cd46을 표적화하는 면역접합체 및 이의 사용 방법 |
| CA3193421A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| EP4221842A4 (en) | 2020-10-02 | 2024-11-20 | Dracen Pharmaceuticals, Inc. | LYOPHILIZED COMPOSITION CONTAINING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR SUBCUTANEOUS ADMINISTRATION AND ITS USE |
| WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
| CA3196243A1 (en) | 2020-10-20 | 2022-04-28 | Angela Marinetti | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
| EP4232019A1 (en) | 2020-10-23 | 2023-08-30 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| EP4240424A1 (en) | 2020-11-04 | 2023-09-13 | Heidelberg Pharma Research GmbH | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
| KR20230104220A (ko) | 2020-11-05 | 2023-07-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법 |
| US20240002509A1 (en) | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| AU2021377699A1 (en) | 2020-11-13 | 2023-06-15 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| MX2023005528A (es) | 2020-11-17 | 2023-06-23 | Seagen Inc | Metodos de tratamiento del cancer con una combinacion de tucatinib y un anticuerpo anti-pd-1/anti-pd-l1. |
| WO2022106505A1 (en) | 2020-11-18 | 2022-05-27 | Institut Curie | Dimers of biguanidines and their therapeutic uses |
| AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
| WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| WO2022130182A1 (en) | 2020-12-14 | 2022-06-23 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| EP4267617A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Human ccr8 binders |
| EP4267618A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Non-blocking human ccr8 binders |
| WO2022136650A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Murine cross-reactive human ccr8 binders |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
| JP2024504923A (ja) | 2021-01-11 | 2024-02-02 | シンセカイン インコーポレイテッド | 受容体ペア形成に関する組成物および方法 |
| IL304031A (en) | 2021-01-14 | 2023-08-01 | Inst Curie | Her2 single domain antibodies variants and cars thereof |
| CA3205538A1 (en) | 2021-01-19 | 2022-07-28 | Han XIAO | Bone-specific delivery of polypeptides |
| US20250282870A1 (en) | 2021-01-20 | 2025-09-11 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
| CA3203705A1 (en) | 2021-01-22 | 2022-07-28 | Erik Hans MANTING | Methods of tumor vaccination |
| US20240384350A1 (en) | 2021-01-29 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods of treating cancer with kinase inhibitors |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| WO2022187423A1 (en) | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
| US20240190874A1 (en) | 2021-03-03 | 2024-06-13 | The Regents Of The University Of Michigan | Small molecule degraders of androgen receptor |
| US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022216979A1 (en) | 2021-04-08 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| EP4070799A1 (en) | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions for the improvement of sport performance |
| WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| EP4079310A1 (en) | 2021-04-20 | 2022-10-26 | Nuvamid SA | Nmn and derivatives for its use in the treatment of alpha-synucleinopathies |
| EP4079311B1 (en) | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
| JP2024515220A (ja) | 2021-04-26 | 2024-04-05 | セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー | 高分子薬剤化合物の持続放出用の埋め込み型デバイス |
| US20240207304A1 (en) | 2021-04-28 | 2024-06-27 | Mina Therapeutics Limited | Combination Therapies Comprising C/EBP Alpha saRNA |
| WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
| EP4341699A1 (en) | 2021-05-18 | 2024-03-27 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
| WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
| CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| CA3222362A1 (en) | 2021-06-10 | 2022-12-15 | Ono Pharmaceutical Co., Ltd. | Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitory substance, and standard therapy |
| EP4528280A3 (en) | 2021-06-14 | 2025-07-02 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| CA3220353A1 (en) | 2021-06-25 | 2022-12-29 | Chugai Seiyaku Kabushiki Kaisha | Use of anti-ctla-4 antibody |
| AR126220A1 (es) | 2021-06-25 | 2023-09-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-ctla-4 |
| EP4367269A1 (en) | 2021-07-05 | 2024-05-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CA3226163A1 (en) | 2021-07-14 | 2023-01-19 | Synthekine, Inc. | Methods and compositions for use in cell therapy of neoplastic disease |
| WO2023014922A1 (en) | 2021-08-04 | 2023-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
| CA3227880A1 (en) | 2021-08-05 | 2023-02-09 | Marios SOTIROPOULOS | Scanning dynamic device for minibeams production |
| MX2024002281A (es) | 2021-08-23 | 2024-05-20 | Immunitas Therapeutics Inc | Anticuerpos anti-cd161 y usos de los mismos. |
| CN118715440A (zh) | 2021-08-31 | 2024-09-27 | 雅培实验室 | 诊断脑损伤的方法和系统 |
| AU2022339759A1 (en) | 2021-08-31 | 2024-03-07 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
| US20240316061A1 (en) | 2021-09-17 | 2024-09-26 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
| KR20240116708A (ko) | 2021-10-05 | 2024-07-30 | 사이토비아 테라퓨틱스, 엘엘씨. | 자연 살해 세포 및 이의 사용 방법 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023068382A2 (en) | 2021-10-20 | 2023-04-27 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| AU2022369312A1 (en) | 2021-10-20 | 2024-05-02 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
| US20240409934A1 (en) | 2021-10-25 | 2024-12-12 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
| CA3234821A1 (en) | 2021-10-28 | 2023-05-04 | Suman Kumar VODNALA | Methods for culturing immune cells |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| MX2024005080A (es) | 2021-10-29 | 2024-05-13 | Seagen Inc | Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco. |
| CN113907045B (zh) * | 2021-11-09 | 2023-01-06 | 派生特（福州）生物科技有限公司 | 一种新品系猪的培育方法及其应用 |
| EP4433089A1 (en) | 2021-11-19 | 2024-09-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| AU2022396272A1 (en) * | 2021-11-24 | 2024-06-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| JP2025503439A (ja) | 2021-12-17 | 2025-02-04 | アボット・ラボラトリーズ | 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法 |
| WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
| JP2025503962A (ja) | 2022-01-26 | 2025-02-06 | ブリストル－マイヤーズ スクイブ カンパニー | 肝細胞がんのための併用療法 |
| US20250099588A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| AU2023216317A1 (en) | 2022-02-04 | 2024-09-05 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| WO2023161453A1 (en) | 2022-02-24 | 2023-08-31 | Amazentis Sa | Uses of urolithins |
| JP2025507694A (ja) | 2022-02-25 | 2025-03-21 | ブリストル－マイヤーズ スクイブ カンパニー | 結腸直腸癌に対する組み合わせ療法 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| AU2023230110A1 (en) | 2022-03-08 | 2024-10-24 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| JP2025509832A (ja) | 2022-03-15 | 2025-04-11 | コンピュジェン リミテッド | Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用 |
| CA3255411A1 (en) | 2022-03-16 | 2025-03-04 | Daiichi Sankyo Co Ltd | COMBINATION OF MULTISPECIFIC MOLECULES AND AN IMMUNE CHECKPOINT INHIBITOR |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| CA3254182A1 (en) | 2022-03-24 | 2023-09-28 | Univ Paris Cite | Immunotherapy targeting neoantigenic peptides derived from a tumor-specific transposable element in a glioblastoma |
| US20250213614A1 (en) | 2022-03-31 | 2025-07-03 | Institut Curie | Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression |
| WO2023196988A1 (en) | 2022-04-07 | 2023-10-12 | Modernatx, Inc. | Methods of use of mrnas encoding il-12 |
| US20250222106A1 (en) | 2022-04-07 | 2025-07-10 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| JP2025511383A (ja) | 2022-04-07 | 2025-04-15 | アンスティテュ キュリィ | キメラ抗原受容体で改変された骨髄系細胞及び抗がん治療のためのその使用 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics Inc | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| AR129136A1 (es) | 2022-04-26 | 2024-07-17 | Novartis Ag | Anticuerpos multiespecíficos que se dirigen a il-13 e il-18 |
| WO2023211972A1 (en) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Chimeric antigen receptor modified regulatory t cells for treating cancer |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| US20250302982A1 (en) | 2022-05-06 | 2025-10-02 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
| CN119255825A (zh) | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2023240156A1 (en) | 2022-06-08 | 2023-12-14 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
| WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| JP2025524992A (ja) | 2022-07-28 | 2025-08-01 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲートと二重特異性チェックポイント阻害剤との組み合わせ |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| WO2024040175A1 (en) | 2022-08-18 | 2024-02-22 | Pulmatrix Operating Company, Inc. | Methods for treating cancer using inhaled angiogenesis inhibitor |
| KR20250052397A (ko) | 2022-08-23 | 2025-04-18 | 오노 야꾸힝 고교 가부시키가이샤 | 이중 특이성 항체 |
| CN117618555A (zh) * | 2022-08-31 | 2024-03-01 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗ctla-4抗体联合用于治疗肿瘤中的应用 |
| WO2024052356A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer |
| CA3265992A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Lab | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND VERY MILD TRAUMATIC BRAIN INJURY |
| WO2024068617A1 (en) | 2022-09-26 | 2024-04-04 | Institut Curie | Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy |
| WO2024086827A2 (en) | 2022-10-20 | 2024-04-25 | Repertoire Immune Medicines, Inc. | Cd8 t cell targeted il2 |
| WO2024084013A1 (en) | 2022-10-20 | 2024-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination therapy for the treatment of cancer |
| CN120187759A (zh) | 2022-11-01 | 2025-06-20 | 海德堡医药研究有限责任公司 | 抗gucy2c抗体及其用途 |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
| IL320733A (en) | 2022-11-21 | 2025-07-01 | Iovance Biotherapeutics Inc | Two-dimensional processes for expanding tumor-infiltrating lymphocytes and treatments thereof |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| AU2023409221A1 (en) | 2022-12-21 | 2025-06-12 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| KR20250152101A (ko) | 2023-03-13 | 2025-10-22 | 하이델베르크 파마 리서치 게엠베하 | 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024194401A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Vps4b inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194402A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194673A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Methods for the treatment of dedifferentiated liposarcoma |
| WO2024211475A1 (en) | 2023-04-04 | 2024-10-10 | Abbott Laboratories | Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi) |
| WO2024213782A1 (en) | 2023-04-13 | 2024-10-17 | Institut Curie | Methods for the treatment of t-cell acute lymphoblastic leukemia |
| WO2024213767A1 (en) | 2023-04-14 | 2024-10-17 | Institut National de la Santé et de la Recherche Médicale | Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors |
| WO2024226971A1 (en) | 2023-04-28 | 2024-10-31 | Abbott Point Of Care Inc. | Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
| WO2025003193A1 (en) | 2023-06-26 | 2025-01-02 | Institut National de la Santé et de la Recherche Médicale | Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025006811A1 (en) | 2023-06-27 | 2025-01-02 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| WO2025012417A1 (en) | 2023-07-13 | 2025-01-16 | Institut National de la Santé et de la Recherche Médicale | Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025050009A2 (en) | 2023-09-01 | 2025-03-06 | Children's Hospital Medical Center | Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens |
| WO2025052098A1 (en) | 2023-09-08 | 2025-03-13 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025068393A1 (en) | 2023-09-27 | 2025-04-03 | Institut Curie | Methods for the treatment of fibrotic related diseases |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025133175A1 (en) | 2023-12-21 | 2025-06-26 | Egle Therapeutics | Immunocytokine for cancer treatment |
| EP4574165A1 (en) | 2023-12-21 | 2025-06-25 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
| WO2025158077A1 (en) | 2024-01-26 | 2025-07-31 | Institut Curie | Lipid degraders to trigger ferroptosis in cancer |
| WO2025163468A1 (en) | 2024-01-30 | 2025-08-07 | Seagen Inc. | Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| WO2025174825A2 (en) | 2024-02-12 | 2025-08-21 | Aera Therapeutics, Inc. | Delivery compositions |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025188693A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Bicyclic tlr7 agonists and uses thereof |
| US20250282786A1 (en) | 2024-03-05 | 2025-09-11 | Bristol-Myers Squibb Company | Tricyclic TLR7 Agonists and Uses Thereof |
| WO2025191529A1 (en) | 2024-03-14 | 2025-09-18 | Biohaven Therapeutics Ltd. | Next generation riluzole prodrugs |
| WO2025202222A1 (en) | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025202450A1 (en) | 2024-03-28 | 2025-10-02 | Institut Curie | Myeloid cells modified by cytokine chimeric receptor and uses thereof |
| EP4624494A1 (en) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2 single domain antibody and uses thereof |
| WO2025210175A1 (en) | 2024-04-04 | 2025-10-09 | Centre National De La Recherche Scientifique | Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof |
| WO2025210252A1 (en) | 2024-04-05 | 2025-10-09 | Institut Curie | Modulators of fam118b protein for use in therapy |
| WO2025217096A1 (en) | 2024-04-08 | 2025-10-16 | University Of Rochester | Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof |
| WO2025217094A1 (en) | 2024-04-08 | 2025-10-16 | University Of Rochester | Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof |
| WO2025219595A1 (en) | 2024-04-19 | 2025-10-23 | Biper Therapeutics | Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy |
| WO2025232879A1 (en) | 2024-05-10 | 2025-11-13 | Cytocares (Shanghai) Inc. | Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| WO2025248505A1 (en) | 2024-05-31 | 2025-12-04 | Wayne State University | Methods for treating endometrial and ovarian hyperproliferative disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020001604A1 (en) | 1998-04-01 | 2002-01-03 | Keijiro Shigeru | Antibacterial, antifungal or antialgal article and process for producing same |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| DE3708238A1 (de) | 1987-03-16 | 1988-09-29 | Motoren Werke Mannheim Ag | Kraft-waerme-kopplungsanlage |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| GB8912497D0 (en) | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| DK0606217T4 (da) | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| EP0592677B1 (en) | 1992-02-18 | 2001-11-07 | Otsuka Kagaku Kabushiki Kaisha | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69425890D1 (de) | 1993-06-04 | 2000-10-19 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| WO1995001994A1 (en) | 1993-07-09 | 1995-01-19 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
| JPH09500788A (ja) | 1993-07-26 | 1997-01-28 | ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド | Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JPH09510211A (ja) | 1994-03-08 | 1997-10-14 | ダナ−ファーバー・キャンサー・インスティテュート | Ｔ細胞の不応答性を調節する方法 |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| KR19980701536A (ko) | 1995-01-20 | 1998-05-15 | 케더린 세레다 글라우브 | 융합된 세포에서 스크린 효과를 개선시키는 방법 |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| JP4312259B2 (ja) * | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) * | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5618912A (en) * | 1995-05-04 | 1997-04-08 | Pennzoil Products Company | Tire sealer and inflator compositions |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| CA2230759C (en) * | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| DE69835145T2 (de) | 1997-02-28 | 2007-06-14 | Kirin Beer K.K. | Transgene Mäuse die ein menschliches Antikörper exprimieren |
| WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| AU7228398A (en) | 1997-04-11 | 1998-11-11 | John P. Robarts Research Institute, The | Lck serine phosphorylation assay for t-cell activation and activation-induced cell death |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2205680A1 (en) | 1997-05-16 | 1998-11-16 | The University Of Western Ontario | Clip immunomodulatory peptide |
| CA2241621A1 (en) | 1998-06-26 | 1999-12-26 | National Silicates Ltd. | A lubricating method for silicate drilling fluids |
| TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
| AU774962B2 (en) * | 1998-12-03 | 2004-07-15 | Regents Of The University Of California, The | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2000037504A2 (en) * | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| US9169311B2 (en) | 2013-03-15 | 2015-10-27 | Applied Food Biotechnology, Inc. | Feline bitter taste receptors and methods |
| KR102264548B1 (ko) | 2014-11-21 | 2021-06-16 | 삼성전자주식회사 | 반도체 패키지 및 그 제조 방법 |
-
2000
- 2000-08-24 EP EP00959399A patent/EP1212422B1/en not_active Expired - Lifetime
- 2000-08-24 IL IL14807900A patent/IL148079A0/xx active IP Right Grant
- 2000-08-24 CN CN008120374A patent/CN1371416B/zh not_active Expired - Lifetime
- 2000-08-24 JP JP2001518753A patent/JP4093757B2/ja not_active Expired - Lifetime
- 2000-08-24 EP EP06077179A patent/EP1792991A1/en not_active Withdrawn
- 2000-08-24 KR KR1020067017019A patent/KR100942863B1/ko not_active Expired - Lifetime
- 2000-08-24 DK DK00959399T patent/DK1212422T3/da active
- 2000-08-24 CA CA002589418A patent/CA2589418A1/en not_active Abandoned
- 2000-08-24 CN CN201210037538.0A patent/CN102766210B/zh not_active Expired - Lifetime
- 2000-08-24 KR KR1020097003898A patent/KR100996759B1/ko not_active Expired - Lifetime
- 2000-08-24 DE DE60033530T patent/DE60033530T2/de not_active Expired - Lifetime
- 2000-08-24 NZ NZ517202A patent/NZ517202A/en not_active IP Right Cessation
- 2000-08-24 MX MXPA02001911A patent/MXPA02001911A/es active IP Right Grant
- 2000-08-24 KR KR1020027002451A patent/KR20020047132A/ko not_active Ceased
- 2000-08-24 PT PT00959399T patent/PT1212422E/pt unknown
- 2000-08-24 AT AT00959399T patent/ATE354655T1/de active
- 2000-08-24 US US09/644,668 patent/US6984720B1/en not_active Expired - Lifetime
- 2000-08-24 CA CA002381770A patent/CA2381770C/en not_active Expired - Lifetime
- 2000-08-24 ES ES00959399T patent/ES2282133T3/es not_active Expired - Lifetime
- 2000-08-24 EP EP17152917.5A patent/EP3214175A1/en not_active Withdrawn
- 2000-08-24 WO PCT/US2000/023356 patent/WO2001014424A2/en not_active Ceased
- 2000-08-24 EP EP14180954.1A patent/EP2829609A1/en not_active Withdrawn
- 2000-08-24 AU AU70732/00A patent/AU784012B2/en not_active Expired
-
2002
- 2002-02-10 IL IL148079A patent/IL148079A/en active Protection Beyond IP Right Term
- 2002-02-12 ZA ZA200201190A patent/ZA200201190B/en unknown
-
2006
- 2006-02-06 JP JP2006029057A patent/JP2006151993A/ja not_active Withdrawn
- 2006-04-11 AU AU2006201520A patent/AU2006201520B9/en not_active Expired
-
2007
- 2007-04-19 CY CY20071100636T patent/CY1107628T1/el unknown
-
2008
- 2008-02-20 IL IL189629A patent/IL189629A0/en unknown
-
2009
- 2009-04-30 JP JP2009111655A patent/JP5599158B2/ja not_active Expired - Lifetime
- 2009-06-18 AU AU2009202447A patent/AU2009202447B2/en not_active Expired
-
2011
- 2011-12-29 JP JP2011290230A patent/JP2012100674A/ja active Pending
-
2012
- 2012-01-05 DE DE201212000001 patent/DE122012000001I1/de active Pending
- 2012-01-09 LU LU91928C patent/LU91928I2/fr unknown
- 2012-01-09 BE BE2012C001C patent/BE2012C001I2/fr unknown
- 2012-01-10 FR FR12C0004C patent/FR12C0004I2/fr active Active
- 2012-01-10 CY CY2012002C patent/CY2012002I2/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020001604A1 (en) | 1998-04-01 | 2002-01-03 | Keijiro Shigeru | Antibacterial, antifungal or antialgal article and process for producing same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100942863B1 (ko) | 인간 씨티엘에이-4 항체 및 그의 용도 | |
| US20020086014A1 (en) | Human CTLA-4 antibodies and their uses | |
| CA2430013C (en) | Transgenic transchromosomal rodents for making human antibodies | |
| HK1048831B (en) | Human ctla-4 antibodies and their uses | |
| KR20070017586A (ko) | ＨＥＲ2/ｎｅｕ에 대한 인간 모노클로날 항체 | |
| HK1064708B (en) | Transgenic transchromosomal rodents for making human antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20060824 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061009 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20080221 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20081129 Patent event code: PE09021S01D |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20090225 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090610 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20091130 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20100209 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20100209 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20130117 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130117 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140121 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150119 Start annual number: 6 End annual number: 6 |
|
| A101 | Application to extend term of patent right by permit | ||
| PA0101 | Application to register extension of term of patent right by permit, etc. |
Patent event date: 20150305 Patent event code: PA01011R01D Comment text: Application to Register Extension of Term of Patent Right by Permit, etc. |
|
| FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160119 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170119 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180118 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190116 Start annual number: 10 End annual number: 10 |
|
| PC1801 | Expiration of term |
Termination date: 20210517 Termination category: Expiration of duration |